Oslo, Norway, 4 June 2026. Reference is made to the stock exchange announcement
published 1 June 2026 by EXACT Therapeutics AS (the "Company", Euronext Growth
ticker: EXTX), a clinical-stage precision medicine company, announcing that
Company will host a webcast in connection with the proposed delisting of the
Company's ordinary shares from Euronext Growth, Oslo on Thursday, 4 June 9.30
CEST.
The presentation will be held by the Chair of the Board, Anders Wold; the
Company's CEO, Per Walday; and CFO, John M. Edminson.
Attached is the presentation for the webcast.
The presentation will also be available on the Company homepage:
www.exact-tx.com
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com
herapeutics\
Email: per.walday@exact-tx.com\